announced

Takeda’s Zasocitinib Shows Consistent Skin Clearance in Phase 3 Psoriasis Studies

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies Takeda announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and…

Read MoreTakeda’s Zasocitinib Shows Consistent Skin Clearance in Phase 3 Psoriasis Studies
Medifast®

Medifast® Enters a New Era with Trilivy™: A Science-Backed System for Metabolic Health

Medifast® Enters a New Era: Introducing Trilivy™, a Science-Backed Metabolic Health System Medifast, Inc. announced the launch of Trilivy, a comprehensive metabolic health system uniquely designed to support healthy lifestyle change. The launch also introduces newly formulated meal replacements, including the Trilivy…

Read MoreMedifast® Enters a New Era with Trilivy™: A Science-Backed System for Metabolic Health
Cellares

Cellares and Sonoma Biotherapeutics Partner to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy

Cellares and Sonoma Biotherapeutics Collaborate to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy on the Cell Shuttle® Platform Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T…

Read MoreCellares and Sonoma Biotherapeutics Partner to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy

Tavoron Strengthens Industrial Automation Portfolio with Acquisition of Fluidraulics

Tavoron Expands Automation Capabilities with Acquisition of Fluidraulics Tavoron, a national leader in industrial automation, robotics, compressed air, motion control and engineered solutions, announced the acquisition of Fluidraulics Inc., an automation component and system distributor that has served customers across…

Read MoreTavoron Strengthens Industrial Automation Portfolio with Acquisition of Fluidraulics

Charles River to Provide NGS Services to Arovella Therapeutics, Advancing Development of Innovative Cancer Therapies

Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches Charles River Laboratories International, Inc. announced a collaboration with Arovella Therapeutics Ltd a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS)…

Read MoreCharles River to Provide NGS Services to Arovella Therapeutics, Advancing Development of Innovative Cancer Therapies
CEL-SCI to Initiate FDA

CEL-SCI to Initiate FDA Registration-Enabling Phase 3 Confirmatory Trial for Multikine® in Newly Diagnosed Head and Neck Cancer

CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer CEL-SCI Corporation announced it is launching its global Confirmatory Registration Study of Multikine® (Leukocyte Interleukin, Injection)* as a neoadjuvant treatment…

Read MoreCEL-SCI to Initiate FDA Registration-Enabling Phase 3 Confirmatory Trial for Multikine® in Newly Diagnosed Head and Neck Cancer
Amprion and Modality.AI Break New Ground in Multimodal Assessment for Neurodegenerative Disease

Amprion and Modality.AI Pioneer a New Era in Multimodal Assessment for Neurodegenerative Disease

Amprion and Modality.AI Break New Ground in Multimodal Assessment for Neurodegenerative Disease Amprion, a global leader in the diagnosis of neurodegenerative disorders through seed amplification testing, and Modality.AI, a leader in AI-enabled multimodal clinical assessments, announced a collaboration to explore…

Read MoreAmprion and Modality.AI Pioneer a New Era in Multimodal Assessment for Neurodegenerative Disease